Berenberg says Mounjaro maker Lilly has further upside
The bank argues Eli Lilly can keep gaining as the GLP-1 obesity and diabetes market expands.
The wire
- 01Berenberg reiterated a bullish view on Eli Lilly, maker of Mounjaro.
- 02Signals sell-side confidence that GLP-1 demand growth is not yet exhausted.
- 03Execution against supply and competitive entrants remains the open question.
From the source
Read at news.google.comMounjaro's maker has more room to run amid GLP-1 boom, Berenberg says